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Background: World-wide, the notable expansion of HIV/AIDS treatment programs in resource-limited settings has
lead to an increasing number of patients in need of second-line cART. To adequately address and prepare for this
scenario, critical assessments of the outcomes of second-line cART are particularly relevant in settings where
monitoring strategies may be inadequate. We evaluated virologic outcomes of second-line combination antiretroviral
therapy (cART) among HIV-infected individuals from Brazil.
Methods: This study was conducted at the Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo
Cruz, at Rio de Janeiro, Brazio. For this study we included all patients who started first-line and second-line cART
between 2000 and 2013. Second-line cART required a switch in the anchor drug of first-line cART. We evaluated time
from second-line start to virologic failure and factors associated with increased risk of failure using multivariable Cox
proportional hazards regression models.
Results: Among the 1,311 patients who started first-line cART a total of 386 patients (29.5%) initiated second-line cART,
out of which 35.0% and 60.6% switched from their first-line to their second-line cART when their HIV RNA was
undetectable and after documented virologic failure, respectively. At second line cART initiation, median age was
38 years [interquartile range (IQR): 31-45years]. Median CD4 count was significantly different for patients starting
second-line cART undetectable [412 cells/mm3 (IQR: 240-617)] compared to those starting second-line cART after
documented virologic failure [230 cells/mm3 (IQR: 118-322.5)] (p < 0.01). Median time from second-line cART initiation
to failure was also significantly different for patients starting second-line cART undetectable compared to those who
with documented virologic failure (log-rank test p < 0.01). Multivariable Cox models showed that younger age, lower
education, and HIV RNA level were independently associated with an increased hazard of second-line failure among
those with documented virologic failure at start of second-line cART.
Conclusions: We have shown that in a middle-income country with universal access to cART, having a detectable HIV
RNA at the start of second-line cART as well as younger age and lower education negatively impact second-line
outcomes. Our findings could guide HIV treatment efforts as to which strategies would help maximize the durability of
these regimens.
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Globally, studies addressing second-line combination
antiretroviral (cART) virologic, immunologic and cli-
nical outcomes have become increasingly common in
recent years [1-5]. Resource-limited settings have ex-
panded their HIV/AIDS treatment programs leading to
an increasing number of patients in need of second-
line cART. Currently, boosted protease inhibitors (PI)-
containing regimens are the recommended option after
first-line cART failure for patients treated in the public
sector in most resource-limited settings [6]. Given the
first-line cART usually available in resource-limited
settings, concerns over the development of resistance
to second-line cART have been raised, particularly in
the absence of (or in the presence of insufficient) viral
load monitoring [7,8]. Indeed, the emergence of drug
resistance has been a major threat to the sustained ef-
fectiveness of cART in resource-rich settings [9] and
the continuation of a failing regimen may be associated
with more complex mutation patterns as observed in
several studies [10-12]. A critical assessment of the
outcomes of second-line cART in resource-limited set-
tings is timely as treatment programs are relatively
new or maturing and monitoring strategies are still in-
adequate [13,14].
Second-line cART accounts for less than 5% of total
antiretroviral treatments in resource-limited settings
[15]. In Latin America and the Caribbean region, the
percentage of individuals receiving second-line cART is
higher than that reported in other resource-limited set-
tings (27% of the patients, ranging from 4 to 43%, are
receiving second-line regimens compared with 0.05% in
other regions of world) [16]. This may in part be due to
specific characteristics of the Americas region, such as
the age of national programs, with many patients star-
ting cART before 2000, as well as with an access to a
broader options of drugs. In 1996, Brazil was the first
middle-income country to implement a universal access
cART while also providing immunologic and virologic
monitoring and resistance testing after first-line failure.
Currently, over 300,000 patients are on cART, using
first-, second-, third-line and salvage regimens, and
roughly 30,000 patients initiate treatment yearly. Never-
theless, no data is available on second-line treatment
outcomes within the routine care provided through the
public health system. An understanding of factors asso-
ciated with second-line cART outcomes in our setting is
critical to guide the evolution of the Brazilian HIV Treat-
ment Program, as well as to maximize the durability of
these regimens, preventing disease progression and redu-
cing mortality. Accordingly, this study describes second-
line cART outcomes in a large urban cohort from Rio de
Janeiro, Brazil, including time to failure as well as factors
associated with treatment failure.Methods
Description of the clinical cohort
This study was conducted at the Instituto Nacional de
Infectologia Evandro Chagas, Fundação Oswaldo Cruz
(INI/FIOCRUZ, formerly known as Evandro Chagas
Clinical Research Institute), where care has been pro-
vided to HIV/AIDS patients since 1986. INI is one of the
largest infectious diseases research centers in Brazil,
where over five thousand HIV infected patients have
been treated since the beginning of the AIDS epidemic.
An observational, longitudinal, clinical database is main-
tained on patients receiving primary and specialized HIV
care at the clinic. Details and results of the HIV/AIDS Cli-
nical Cohort can be found elsewhere [17]. INI’s Institutional
Review Board reviewed and approved the study and pa-
tients provided written informed consent.
Study population and definitions
For this study we included all patients who started first-
line cART between January 01, 2000 and June 30, 2010.
Follow-up information included data up to December 30,
2013. Included patients had to be at least 18 years old at
cohort enrollment and have followed first-line cART by a
second-line cART regimen. First- and second-line cART
regimens were defined as two or more nucleoside reverse
transcriptase inhibitors (NRTI) plus an anchor drug [i.e., a
nonnucleoside reverse transcriptase inhibitor (NNRTI), or
a protease inhibitor (PI)]. Patients were treated according
to the Brazilian HIV Treatment Guidelines that recom-
mend as a preferred first-line cART a regimen based on
NNRTIs though PI-based regimens can also be prescribed.
In contrast, second-line cART, according to the guideline,
should be PI-based though NNRTI-based regimens can
also alternatively be prescribed [18].
Second-line cART was defined for individuals who
either failed first-line cART (HIV RNA viral load mea-
surement > 400 copies/mL after 5 months of initiating
first-line cART) and subsequently switched their regi-
men class and/or drug, depending on the class of the
first-line cART as detailed below, or for patients who
had not failed their first-line cART but switched their
regimen class and/or drug, depending on the class of the
first-line cART as detailed below. Patients who started a
first-line NNRTI-based regimen were assumed to have
switched to second-line cART if a PI-based regimen was
started. Alternatively, patients who started a first-line
PI-based regimen were assumed to have switched to
second-line cART if either a NNRTI-based regimen was
started or there was a switch of the PI drug used. Modi-
fications to the NRTIs backbone, that is, in any or all
NRTIs alone, were not considered as switches from first
to second-line cART. Also, the addition of ritonavir to a
PI-based first-line regimen was not considered as a
switch from first to second line cART.
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date of the second-line cART. The definition of virologic
failure for second-line cART was conditional on the HIV
RNA level at the start of the second-line cART regimen.
For patients with an HIV RNA of >400 copies/ml at the
start of second-line cART, virologic failure was defined
as an HIV RNA level of >400 copies/ml after 5 months
of start of second-line cART. For patients with an
HIV RNA of ≤ 400 copies/ml at the start of second-
line cART, virologic failure was defined as an HIV
RNA > 400 copies/ml after 2 months of start of second-
line cART. Two scenarios were defined as virologic fail-
ure while on second line cART: a single HIV RNA > 400
copies/mL followed by a regimen class modification as
well as having two consecutive HIV RNAs > 400 copies/
mL regardless if a regimen class modification had oc-
curred or not. A single HIV RNA > 400 copies/mL
followed by a subsequent HIV RNA of < 400 copies/mL
with no regimen class modification was considered a
blip. The median time between the two HIV RNA mea-
surements was 4 months (mean of 6 months, interquar-
tile range 2-7 months). Standard of care adherence
counseling was provided by the attending physician
once virologic failure was detected, as per local guide-
lines. Deaths from AIDS-related causes were defined as
virologic failures while deaths from non-AIDS-related
causes were defined as censored observations. Cen-
soring was also applied in two situations. First, patients
who did not fail assuming the definitions above were
censored at the date of the last viral load plus six
months. Second, patients who did not have a an HIV
RNA result or any documented switch in regimen class
were censored after the grace periods described above
(patients with an HIV RNA of > 400 copies/ml at the
start of second-line cART were censored at 5 months
and patients with an HIV RNA of < 400 copies/ml at the
start of second-line cART were censored at 2 months).
The limit of detection of viral load assays used through-
out the study period varied from < 400 to < 50 copies/
ml. For consistency, we have used the <400 copies/ml
threshold for the entire study period.
Genotype testing
For this study, we included genotype testing results
available in patient’s medical chart. Genotype testing
was performed at the Laboratory of AIDS and Mole-
cular Immunology, at the Oswaldo Cruz Institute, which
is part of RENAGENO (the Brazilian National Network
for genotyping, a network of laboratories implemented
in 2001 by the Ministry of Health). The genotyping
assays used were ViroSeq® and TrueGene®. Both tests
employ DNA sequencing methodology and are ap-
proved and validated; most tests were performed with
TRUGENE Kit®.Statistical analysis
Basic bivariate analysis included performing the Pearson’s
Chi-square test for categorical variables and the Mann-
Whitney rank sum test for continuous variables. Kaplan-
Meier plots and the log-rank test were used to analyze the
time to predefined outcomes. Cox proportional hazards
regression models were fitted to estimate relative hazards
and 95% confidence intervals of time to second-line cART
virologic failure. To verify the proportionality assumption
in Cox’s model, we tested the correlation between survival
time and Shoenfeld’s standardized residuals. R software
version 3.0.3 (www.r-project.org) was used for all statis-
tical analyses.
Results
Among the 1,311 patients who started first-line cART, a
total of 386 patients (29.5%) initiated second-line cART.
Most patients used a first-line NNRTI-based regimen
(n = 243; 63%) while 143 (37%) used a PI-based regimen,
51% (74/143) of these a non-boosted PI. First-line effec-
tiveness for our cohort of patients has been previously
described [19].
Out of 386 patients who started second-line cART, 135
(35.0%) patients switched from their first-line to second-
line cART when their HIV RNA was undetectable, and
234 patients (60.6%) initiated second-line cART after
documented virologic failure (Table 1). Seventeen patients
(4.4%) did not have an HIV RNA result available before
second-line cART initiation. Reasons for switching first-
line cART were available for 382 patients. The most fre-
quent reason for switching first-line cART were toxicities
(121/382 [31.7%]), 41% and 26% among the undetectable
and detectable groups, respectively. Other reasons for
switching first-line cART were therapeutic failure (inclu-
ding virologic, immunologic or clinical failure, 115/382
[30.1%]), physician’s decision (including drug-drug inter-
action, actual or desired pregnancy, or to improve ad-
herence or for dose convenience, 100/382 [26.2%]), and
patient’s decision (46/382, 12.0%).
At second line cART initiation, median age was
38 years [interquartile range (IQR): 31-45years], 59%
were male and half were non-white (Table 1). The ma-
jority (59%) of patients had less than 8 years of formal
education and the median time since first HIV-positive
test was 3.3 years. Overall, median CD4 count at
second-line cART initiation was 260 cells/mm3 (IQR:
145-425 cell/mm3). The median CD4 count was signifi-
cantly different for patients starting second-line cART
undetectable [412 cells/mm3 (IQR: 240-617)] compared
to those starting second-line cART after documented viro-
logic failure [230 cells/mm3 (IQR: 118-322.5)] (p < 0.01,
Table 1). The median HIV RNA at the time of second-line
for those with virologic failure was 4.4 log10 copies/mL
(IQR: 3.8-5.0 log10 copies/mL).
Table 1 Demographic and clinical characteristics at second-line cART initiation stratified by HIV RNA level, 2000-2013
HIV RNA level
Overall Undetectable Detectable p-value
N (%)* 369 135 234
Age
Median (IQR) 38.3 (31.8-45.2) 38.7 (30.4-45.4) 37.9 (31.9-45.2) 0.93
≤30 78 (21.1) 33 (24.4) 45 (19.2) 0.27
30-39 127 (34.4) 40 (29.6) 87 (37.2)
≥40 164 (44.4) 62 (45.9) 102 (43.6)
Race 0.05
Non white 185 (50.1) 58 (43.0) 127 (54.3)
White 184 (49.9) 77 (57.0) 107 (45.7)
Gender/HIV exposure 0.28
Heterosexual men 110 (28.5) 36 (26.7) 70 (30.7)
Women 127 (33.0) 50 (37.0) 71 (31.1)
MSM 97 (25.0) 38 (28.1) 57 (25.0)
IDU 9 (2.5) 4 (3.0) 5 (2.2)
Other 37 (10.0) 7 (5.2) 25 (11.0)
Education 0.11
≤8 years 219 (59.5) 72 (53.7) 147 (62.8)
>8 years 149 (41.5) 62 (46.3) 87 (37.2)
Years since first HIV+ test 0.80
Median (IQR) 3.3 (1.8-5.8) 3.1 (1.7-5.8) 3.4 (1.9-5.7)
CD4 cell count, cells/mm3 <0.01
Median (IQR) 260 (145, 425) 412 (239, 617) 230 (118, 322)
≤200 110 (34.3) 19 (15.6) 91 (45.7)
201-350 96 (29.9) 31 (25.4) 65 (32.7)
>350 115 (35.8) 72 (59) 43 (21.6)
HIV RNA level*
Log10 copies/ml, median (IQR) N/A N/A 4.4 (3.8-5.0) -
≤400 copies/ml 135 (36.6) 135 (100.0) N/A -
401-10,000 copies/ml 83 (22.5) N/A 83 (35.5)
10,001-100,000 copies/ml 97 (26.3) N/A 97 (41.5)
>100,000 copies/ml 54 (14.6) N/A 54 (23.0)
Change in anchor drug from 1st to 2nd line <0.01
NNRTI to PI-r 204 (55.3) 50 (37) 154 (65.8)
NNRTI to PI 27 (7.3) 13 (9.6) 14 (6)
PI/PI-r to NNRTI 73 (19.8) 42 (31.1) 31 (13.2)
PI/PI-r to PI/PI-r 65 (17.6) 30 (22.2) 35 (15)
Calendar year 0.97
2000-2006 154 (41.7) 57 (42.2) 97 (41.5)
2007-2013 215 (58.3) 78 (57.8) 137 (58.5)
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(Continued)
Days from 1st line failure to 2nd line initiation -
Median (IQR) N/A N/A 173 (0.0-606)
*17 patients did not have an HIV RNA result prior to starting second-line cART.
Abbreviations: HIV human immunodeficiency virus, MSM men who have sex with men, IDU injection drug user, ART antiretroviral therapy
Gender and reported mode of HIV exposure were categorized jointly into women, heterosexual men, MSM, IDU (men and women) and other reported modes of
HIV exposure (men and women). Individuals reporting both IDU and other modes of HIV exposure were categorized into IDU.
Education was self-reported and based on the number of years of formal education.
CD4 cell count was defined as the CD4 cell count closest to the date of start the second line cART up to 30 days after.
HIV RNA was defined as the HIV RNA measurement closest to the date of start second line cART up to 7 days after.
Days from failure of first-line cART to start of second-line cART was assumed to be zero if patients started second-line cART without virologic failure.
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from NNRTI- or PI-based regimens to a boosted PI-based
regimen (73%) and to a much smaller extent from a PI/PI-r
to an NNRTI (19%). Overall, 296 patients (82%) used a PI-
based second-line cART out of which the majority (269/
296, 91%) used a ritonavir-boosted PI (PI-r). Lopinavir/r
was used by 46% (135/296) and ATV/r by 37% (111/296).
The most frequently used NRTI backbones were: AZT/
3TC (197/369, 53%) and 3TC/TDF or FTC/TDF (114/369,
31%). For patients initiating second-line cART with an
undetectable HIV RNA, the most frequent switches were
from NNRTI-based to a boosted PI-based cART (37%)
followed by PI/PI-r to NNRTI-based (31%) and PI/PI-r to
PI/PI-r (22%). For patients who initiated second-line cART
with a detectable HIV RNA, the most frequent modifica-
tion was from NNRTI to a boosted PI-based (65%) cART
(Table 1).
Overall, the median time from first-line cART to
second-line cART was 20.1 months (95% CI 17.1-22.6).
For patients who initiated second-line cART with an un-
detectable HIV RNA, the median time was 20.3 months
(95% 16.7-24.2) and for those who initiated cART with a
detectable HIV RNA, the median time was 20.8 months
(18.4-23.1). The Kaplan-Meier plot of the time from first-
line cART to second-line cART is given in Figure 1; log-
rank test indicated that the curves were not significantly
different (p = 0.58).Figure 1 Time from first-line cART initiation to second-line cART initia
initiation, IPEC cohort, 2000-2013. Log-rank test indicated that curves wAmong the 386 patients who started second-line cART
(median follow-up time of 1.9 years), 199 patients devel-
oped virologic failure, 174 were censored, and 13 patients
died during follow-up due to AIDS-related causes (5 and
6 deaths in the undetectable and detectable groups).
The overall incidence of second-line failure was 12/1000
person-years (95% CI 10-14/1000 person-years). The
incidence of second-line failure was 5.7/1000 person-
years (95% CI 4.2-7.7/1000 person-years) and 19/1000
person-years (95% CI 16-23/1000 person-years) among
those who started second line cART with an undetect-
able and a detectable HIV RNA (incidence rate ratio for
detectable compared to undetectable of 3.4, p < 0.0001).
The overall probability of failure at 12, 24 and 36 months
was 26%, 41% and 48% respectively. For the undetect-
able group, 12-, 24- and 36-months probability of failure
was 15%, 23% and 30% while for the detectable group,
12-, 24- and 36-months probability of failure was 34%,
55% and 62%.
Overall, the median time from second-line cART to vi-
rologic failure was 40.0 months (95% CI 30.4, 52.2). The
median time from second-line cART initiation to failure
was significantly different between the two groups (log-
rank test p < 0.01, Figure 2). For patients who started
second-line cART undetectable, the median time was
113.6 months (lower bound of the 95% CI 82.4 months,
upper bound could not be calculated) and for those whotion stratified by HIV RNA level at time of second-line cART
ere not significantly different (p = 0.58).
Figure 2 Time from second-line cART initiation to virologic failure stratified by HIV RNA level at time of second-line cART initiation,
IPEC cohort, 2000-2013. Log-rank test indicated that curves were significantly different (p < 0.01).
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was 19.8 months (95% CI:15.7-28.6 months). Overall,
the median time from second-line cART initiation to
failure stratified by anchor drug was significantly diffe-
rent (log-rank test p = 0.002, Figure 3). The median time
from second-line cART initiation to failure stratified by
anchor drug was also significantly different for the
undetectable group (log-rank test p < 0.002). In contrast,
for the detectable group, the median time from second-
line cART initiation to failure stratified by anchor drug was
not significantly different (log-rank test p = 0.70). No diffe-
rences were observed in the median time from second-line
cART to AIDS related deaths (25.2 months [95% CI:10.1-
50.8 months] and 23.4 months [95% CI:12.1-40.2] for the
detectable and undetectable groups, respectively [log rank
test p = 0.22]).
Factors associated with second-line cART failure
The hazard ratios (HR) for second-line failure stratified by
HIV RNA level at second-line cART initiation (detectable
and undetectable) are shown in Table 2. For patients who
initiated second-line cART with an undetectable HIV
RNA, age, second-line anchor drug and first-line duration
were independently associated with the hazard of second-
line failure (Table 2). A protective effect was observed for
older age, with a lower HR for those individuals older than
40 years when compared to those younger than 30 years
at second-line initiation (HR 0.44 95% CI 0.22-0.90), as
well as for switching either from PI/PI-r to NNRTI
(HR 0.40 95% CI 0.18-0.85) and PI/PI-r to PI-r (HR 0.39
95% CI 0.15-0.96) when compared to switching from a
NNRTI to a PI-r based regimen. The longer the patient
remained on first-line cART, the lower was the hazard for
second-line failure, with a 3% decrease in the hazard of
failure for each additional month on first line cART. To-
xicity as the reason for switching first-line cART was not
associated with an increased incidence of second-line
cART failure.For patients who initiated second-line cART with a de-
tectable HIV RNA, age and level of education were inde-
pendently associated with the hazard of second-line failure.
Again, a protective pattern was found for older age when
compared to younger individuals and for higher education
when compared to those with less years of education
(Table 2). Whilst not significant, a higher hazard of failure
was observed for patients initiating second-line with an
HIV RNA level between 10,001-100,000 copies/ml, when
compared to those with HIV RNA levels <10,000 copies/ml
(p = 0.06). Time from first-line cART failure to second-
line cART initiation was not associated with the incidence
of second-line cART failure.
Resistance testing
HIV genotyping results at first-line cART failure were
available for 39% (91/234) of the patients who started
second-line cART with a detectable viral load. A geno-
typing result yielding wild type virus was found in 7.7%
(7/91) of patients. Overall, M184V was the most preva-
lent mutation (59/91, 65%). K65R was identified in 38%
of the patients using TDF (8/21) all of which were using
an NNRTI based cART regimen. At least one primary PI
mutation was found for 75% (6/8) and 55% (5/9) of pa-
tients using PI and PI-r cART based regimens. Among
those patients using a NNRTI based regimen, the most
prevalent NNRTI mutation was K103N (43/74, 58%).
Resistance testing results were available for 23% (43/187)
of the patients at second-line cART virologic failure. Over-
all, 32.5% (14/43) of the genotyping results yielded no re-
sistance mutations (wild type virus), and this was higher
among those patients using a boosted PI cART regimen
(12/30, 40%). More than 3 TAMS were identified in
11.6% (5/43). At least one primary PI mutation was
identified in 75% (3/4) of patients using an unboosted
PI cART based regimen (D30N, I50L and 46 V), and
10% (3/30) among those using a PI-r cART regimen
(47 V, 82A and 90 M).
Figure 3 Time from second-line cART initiation to virologic failure stratified by anchor drug received for all patients (top, log-rank test
p = 0.002), the sub-group of patients with an undetectable viral load (middle, log-rank test p < 0.002), and the sub-group of patients
with detectable viral load (bottom, log-rank test p = 0.70), IPEC cohort, 2000-2013.
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Our results show that more than half of our study popula-
tion (60%) started second-line cART after a documented
virologic failure, and that the outcomes from start of
second-line cART were significantly different for patients
who started second-line cART with an undetectablecompared to a detectable HIV RNA. The median time
from second-line cART to failure was significantly higher
for those who started with an undetectable HIV RNA
compared to those with a detectable HIV RNA. In
addition, the incidence of second-line failure was 3.4 times
higher for those with a detectable viral load and the
Table 2 Adjusted hazard ratios and 95% confidence
intervals as estimated by Cox proportional hazards
regression for second-line cART failure stratified by




<30 years Ref. Ref.
30-39 years 0.75 (0.34-1.70) 0.54 (0.35-0.83)
≥40 years 0.44 (0.22-0.90) 0.58 (0.38-0.89)
Education
>8 years Ref.
≤8 years 1.44 (1.01-2.03)









Time from first-line to second-line
initiation
Per 1 month increase 0.97 (0.95-0.99)
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sistently higher for this group. Taken together, these re-
sults clearly point to differences in outcomes as a function
of an individual’s HIV RNA at start of second-line cART
which is in agreement with the findings from a multicen-
ter study with a similar design [20].
Given that an undetectable HIV RNA can be taken as
surrogate marker for treatment response and possibly
good adherence and no viral resistance, it was expected
that patients starting second-line cART undetectable
would show improved outcomes. Indeed, non-adherence
to therapy has been shown to be one of the strongest
predictors of cART failure [21,22]. In this group, the
median time from second-line cART to failure was
113 months, two-fold higher than the 50 months median
time found in a multicenter study from the United
States [20]. Differences in socio-demographic character-
istics, adherence pattern and regimen tolerability may
explain the better outcomes shown in our study. Also, in
our cohort, only 2% were IDUs, while up to 24.2% were
IDUs in the US cohort [20]. Moreover, our study partici-
pants initiated cART on or after the year 2000 when
friendlier regimens were increasingly available.
As for socio-demographic factors impacting second-
line cART outcomes, our results suggest that older ageand higher education were associated with a decreased
hazard of failure. For this sample population, age older
than 30 years at start of second-line cART significantly
decreased the hazard of failure among patients with
detectable and undetectable HIV RNA at second-line
cART start. In a recent analysis of first-line cART con-
ducted by our group, both factors were also found to im-
pact treatment effectiveness [19] and a higher proportion
of viral suppression was detected for older/elderly patients
[23]. In agreement, a protective effect of older age was also
observed in other cohorts both in resource-rich and
resource-limited settings [24,25]. Older age and higher
education are likely correlated with a better understanding
of the importance and value of cART and, consequently,
better treatment adherence [26]. These results are worri-
some given the current epidemiological scenario of the
Brazilian AIDS epidemic which shows an increase of AIDS
cases among the younger and less educated [18]. A better
understanding of the beliefs and barriers to cART adhe-
rence as well as interventions tailored to these specific
populations to improve cART outcomes are urgently
needed.
Our results also show that anchor drug switches from
first-line to second-line cART can impact the hazard of
second-line cART among patients who had an undetec-
table HIV RNA at the start of second-line cART. We
found that patients switching from an NNRTI-based regi-
men to an unboosted PI-based regimen had increased
hazard of failure of second-line cART when compared to
those switching to a boosted-PI-based regimen. In con-
trast, patients were protected from failure if switches were
from unboosted or boosted PI-based regimens to either
NNRTI-based regimens or a boosted PI-based regimen.
These results echo current knowledge since unboosted PI
regimens are no longer an option in contemporary treat-
ment guidelines [6,18]. Our results show that the hazard
of second-line cART failure was lower the longer the
patient stayed on first-line cART. These findings can be
interpreted as being due to a good treatment adherence
which was first evidenced during first-line cART and pos-
sibly extends to second-line. In contrast, for the sub-
group of patients with a detectable HIV RNA, the HIV
RNA level at start of second-line cART led to an increased
hazard of failure with borderline significance. Indeed, HIV
RNA >100,000 copies/mL is well known to be associated
with higher risk of first-line cART virologic failure [27-29]
and second-line cART failure [30,31]. We speculate that
the higher risk of failure among patients with intermediate
HIV RNA level at second-line cART initiation could sug-
gest that this group had more irregular treatment adhe-
rence and, consequently, more viral resistance.
Another finding from our study is that the median
time from first-line to second-line cART was not signifi-
cantly different among those who started second-line
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a detectable HIV RNA, suggesting that concurrent rea-
sons to switch first-line cART occurred overtime which
included toxicities in addition to virologic failure. In fact,
a higher proportion of patients who switched to second-
line cART while having HIV RNA undetectable did so
due to toxicities (41% and 26% among the undetectable
and detectable groups, respectively). A somewhat sur-
prising finding was that the median time from second-
line cART to failure was significantly longer than that of
first-line cART (40 months for second-line compared to
20 months for first-line). This may result from a high
proportion of first-line cART switches due to toxicities.
In previous analyses we have shown that toxicities were
the driving force for first-line cART modifications and/
or interruptions which were highly incident in our co-
hort especially during the first year of cART [32].
Although HIV genotyping tests are available in Brazil
through the Public Health System since 2001, only 39% of
the patients had a resistance test performed after first-line
virologic failure and before starting second-line cART. Also,
a small number of patients (23%) who developed second-
line cART virologic failure had a resistance testing
performed at second-line failure. Several issues such as in-
sufficient laboratory infrastructure, long intervals to receive
the genotyping results, technical limitations related to the
viral load threshold for viral amplification (initially 5,000
copies/mL, only recently changed to 1,000 copies/mL),
among others, may explain the small number of tests
performed. Of note, although our numbers are very small, it
is important to highlight the number of genotyping results
yielding wild type virus among patients using a PI-r cART
regimen at second-line virologic failure. Although boosted
PI cART regimens have a higher genetic barrier against
resistance [33,34], it is well known that poorer adherence may
happen more frequently with this drug class, as a consequence
of the worse tolerability profile, especially with lopinavir/r,
the most frequently used boosted-PI in our cohort.
Our study has strengths and limitations. A major strength
of our study is its large time span, covering 13 years of
cART, in a cohort of HIV-infected patients from a middle-
income country that provides universal access to treatment.
In this scenario we were able to study outcomes of second-
line cART with detailed socio-demographic, laboratory and
treatment data. To the best of our knowledge, this is the
first study of second-line cART outcomes in Brazil and, in
the international literature, possibly one of the few studies
that longitudinally evaluated outcomes of second-line
cART. Lack of adherence data is a major limitation of our
study. Despite this pitfall, given the availability of HIV RNA
measurements, we were capable of using an undetectable
HIV RNA as a proxy for treatment adherence which
allowed us to discuss important findings with respect to
second-line cART. That said, specific treatment adherencemeasures are needed to study its impact as well as to allow
for adherence interventions to be carried out. Current
WHO guidelines recommend that patients presenting with
failure should be subject to adherence support interven-
tions, after which a second viral load test should be
performed prior to deciding on a regimen switch [6]. In this
study, we were not able to consistently use two consecutive
HIV RNA measurements as a definition of virologic failure.
Instead, we used the definition that was feasible and this
could have led to some misclassification of patients as fail-
ures when in fact this would not have been confirmed. In
addition, beyond study definitions, the reality of having only
one measurement available implies that physicians are also
making decisions to switch regimens based on only one
measurement, meaning that patients might be unnecessar-
ily being subject to treatment modifications. Studies have
shown that individuals on first-line cART virologic failure
experienced re-suppression without switching [35]. To
explore these speculations additional studies are needed.
Conclusions
Achieving sustained viral suppression is the objective of any
cART irrespective if it is the first-line or subsequent treat-
ment regimens. The need for lifelong antiretroviral therapy
for HIV infection argues for the use of subsequent regi-
mens with the most favorable efficacy and safety profile,
ideally including drug classes without super-imposable re-
sistance patterns. We have shown that in a middle-income
country with universal access to cART, having a detectable
HIV RNA at the start of second-line cART negatively im-
pacts second-line outcomes and that factors such as
younger age and lower education can also negatively impact
second-line cART outcomes. Although third-line cARTs
such as darunavir, etravirine, raltegravir and maraviroc are
available in Brazil, the costs associated with these drugs are
significantly higher, and treatment regimens frequently
include a larger number of pills, adding further complexity
to treatment management. As such, tailored interventions
to the specific populations here described are critical to
guarantee the benefits of second-line cART.
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